United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Acquires New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• United Super Pty Ltd disclosed a new fourth-quarter stake in Zimmer Biomet, buying 122,735 shares valued at about $11.0 million. The position represented roughly 0.06% of the company.
• Zimmer Biomet’s latest quarterly results beat expectations, with EPS of $2.09 versus the $1.86 consensus and revenue of $2.09 billion, up 9.3% year over year. The company also maintained FY2026 guidance of 8.400–8.550 EPS.
• Analyst sentiment remains mixed: the stock has a current Hold rating overall, with a consensus price target of $102.70. Zimmer Biomet also announced a quarterly dividend of $0.24 per share, payable July 31.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 122,735 shares of the medical equipment provider's stock, valued at approximately $11,036,000. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned approximately 0.06% of Zimmer Biomet at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ZBH. Key Financial Inc increased its holdings in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. increased its holdings in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after acquiring an additional 116 shares during the period. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $32,000. Grove Bank & Trust increased its holdings in Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 328 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Zimmer Biomet during the 2nd quarter worth approximately $37,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZBH shares. William Blair started coverage on Zimmer Biomet in a research note on Friday, February 20th. They set a "market perform" rating for the company. Barclays dropped their price objective on Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating for the company in a research note on Wednesday, April 29th. BTIG Research reissued a "neutral" rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Wall Street Zen raised Zimmer Biomet from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, UBS Group reissued a "sell" rating and issued a $89.00 price target on shares of Zimmer Biomet in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $102.70.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $82.92 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The stock has a market capitalization of $16.04 billion, a price-to-earnings ratio of 21.54, a price-to-earnings-growth ratio of 1.91 and a beta of 0.48. The company has a fifty day moving average of $88.09 and a 200-day moving average of $90.69. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to analysts' expectations of $2.07 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The firm's revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet's payout ratio is 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company's stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.28% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.